

Press release 2012-06-14



A successful C-RAD representation at the DEGRO meeting in Wiesbaden / Germany

C-RAD AB with its five fully owned subsidiaries are all active in the field of radiation therapy. The company attended the meeting from the German Association of Radiation Oncology (DEGRO) in Wiesbaden, Germany, 7-10 June 2012.

The DEGRO is the annual meeting on the largest European Radiotherapy Market in Germany. The conference is attended by Physicians, Physicist and technical personal from Radiotherapy departments mainly from the German speaking countries.

In the booth C-Rad presented the Catalyst System. Many customers were attracted by the announcement that Elekta is choosing C-RAD as the preferred solution for their respiratory gating offer.

Sales projects have been discussed. Further orders can be expected for the next quarter.

Erik Hedlund, CEO, C-RAD AB:

"We saw at the DEGRO meeting that customers are looking for solutions to improve treatments of breast cancer patients. This is an important topic within the community. C-RAD can improve treatments with its Catalyst System and its modules for Positioning and Gating. Positioning has unique features for a reproducible setup on daily basis. Gating is used in advanced treatment techniques to reduce the delivered dose to the cardiac tissue. The strength of the C-RAD solution is the high level of integration in the clinical workflow. "

For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46 (0)18 66 69 31, E-mail erik.hedlund@c-rad.se

About C-RAD AB

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in three fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB. C-RAD Imaging AB is located in Östersund while the other companies are located in Uppsala. Numbers of employees are currently 21 people. The activities in C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta, the US company Varian and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD has founded two companies for direct sales, C-RAD Incorporated in the US and C-RAD GmbH in Germany. C-RAD AB is since March 2010 listed at Nasdaq Omx First North Premier.